<DOC>
	<DOC>NCT00804921</DOC>
	<brief_summary>Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV). Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.</brief_summary>
	<brief_title>Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>macular edema pulmonary chronic problems chronic renal failure intraocular inflammation drug or alcohol addiction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>intra-ocular pressure</keyword>
	<keyword>acetazolamide</keyword>
	<keyword>anterior chamber paracentesis</keyword>
	<keyword>brimonidine</keyword>
	<keyword>macular edema secondary to diabetic retinopathy or macular degeneration</keyword>
</DOC>